Immunomonitoring in volunteers & patients
The “immunomonitoring platform” has developed tools for both human samples as samples from other animal species. As a consequence, Bertin Pharma is able to support the immunological monitoring of patients or healthy volunteers using tools abovementioned. Moreover, our Level-3 security facilities can receive samples at risk.
Immunomonitoring consists of following up immune responses in volunteers or patients after receiving a therapeutic protein, a vaccine, an antibody, a cytokine or any other molecule able to trigger a process of immunomodulation.
This immunological analysis thus spans a wide field of therapeutic applications such as infectious and autoimmune diseases, cancers, transplantations, gene therapies but also treatments for allergic desensitization.
This immunological follow up thus allows:
-
evaluation of the efficacy of treatment (evidence and description of the
effects on the immune system, be they immunostimulating or
immunosuppressing)
-
detailing the cellular or molecular mechanisms that rule this efficacy
-
awareness of the immunogenic power of a therapeutic molecule able to influence its efficacy
-
identification of novel biomarkers that can predict a disease, treatment or vaccine progression
-
to confirm the safety of a treatment (absence of an unexpected modulation of the immune response
From a technological point of view, immunomonitoring allows the characterization and quantification of immune cells (lymphocytes, monocytes, dendritic cells), identification of "rare" sub-population of cells via, for example, flow cytometry techniques combining multiple parameters, and the study of complex immunological functions (cell proliferation, antigen presentation, synthesis of cytokines, of antibodies or other biomarkers, gene expression profiles).
The complexity of the immune system, the advancement of scientific knowledge and the sophistication of exploratory tools render possible a more and more elaborate deciphering immune response to vaccines and other treatments. These approaches imply the development of novel know-how, not only those linked to up to date technologies used, but also to management, validation and safe keeping of gathered data. Their application to clinical trials implies a standardization of techniques and systems of analysis as well as a reflection on the requirements of national and international regulation agencies.
__________________________________________________________________________________________________________
Related services
-
Protein & HCP analysis
-
Immunogenicity
